Evidence map›Paper›PMID 29207110›Full record

ArticleMolecular medicine reports2018

Acetylshikonin suppresses invasion of Porphyromonas gingivalis‑infected YD10B oral cancer cells by modulating the interleukin-8/matrix metalloproteinase axis.

Bong-Hae Cho, Yun-Hoa Jung, Da Jeong Kim, Bok Hee Woo, Ji Eun Jung, Ji Hye Lee, Young Whan Choi, Hae Ryoun Park

Open access · hybridAbstract read
In one paragraph

Article in Molecular medicine reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. The Role ofCancers · 2025
    Review
  3. Article
  4. Article
  5. Advances in Small Molecular Agents against Oral Cancer.Molecules (Basel, Switzerland) · 2024
    Review
  6. Review
  7. Periodontitis and progression of gastrointestinal cancer: current knowledge and future perspective.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023
    Review
  8. Current issues in molecular biology · 2023
    Article
  9. Genome-Wide Identification ofLife (Basel, Switzerland) · 2022
    Article
  10. Review
  11. Article
  12. Review
  13. World journal of clinical cases · 2019
    Review
  14. Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Bong-Hae ChoDepartment of Oral and Maxillofacial Radiology, School of Dentistry, Pusan National University, Yangsan, Gyeongsangnam‑do 50612, Republic of Korea.
Yun-Hoa JungDepartment of Oral and Maxillofacial Radiology, School of Dentistry, Pusan National University, Yangsan, Gyeongsangnam‑do 50612, Republic of Korea.
Da Jeong KimDepartment of Oral Pathology and BK21 PLUS Project, School of Dentistry, Pusan National University, Yangsan, Gyeongsangnam‑do 50612, Republic of Korea.
Bok Hee WooDepartment of Oral Pathology and BK21 PLUS Project, School of Dentistry, Pusan National University, Yangsan, Gyeongsangnam‑do 50612, Republic of Korea.
Ji Eun JungDepartment of Oral Pathology and BK21 PLUS Project, School of Dentistry, Pusan National University, Yangsan, Gyeongsangnam‑do 50612, Republic of Korea.
Ji Hye LeeDepartment of Oral Pathology and BK21 PLUS Project, School of Dentistry, Pusan National University, Yangsan, Gyeongsangnam‑do 50612, Republic of Korea.
Young Whan ChoiDepartment of Horticultural Bioscience, Pusan National University, Miryang, Gyeongsangnam‑do 50463, Republic of Korea.
Hae Ryoun ParkDepartment of Oral Pathology and BK21 PLUS Project, School of Dentistry, Pusan National University, Yangsan, Gyeongsangnam‑do 50612, Republic of Korea.
Pusan National University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The development of pharmaceutical agents possessing anti‑invasive and anti‑metastatic abilities, as well as apoptotic activity, is important in decreasing the incidence and recurrence of oral cancer. Cancer cells are known to acquire invasiveness not only through epigenetic changes, but also from inflammatory stimuli within the tumor microenvironment. Accordingly, the identification of agents that can suppress the inflammation‑promoted invasiveness of cancer cells may be important in treating cancer and improving the prognosis of patients with cancer. Acetylshikonin, a flavonoid with anti‑inflammatory activity, inhibits proliferation and induces apoptosis of oral cancer cells. In the present study, the anti‑invasive effect of acetylshikonin on YD10B oral cancer cells infected with Porphyromonas gingivalis, a major pathogen of chronic periodontitis, and the mechanisms involved were investigated. Firstly, we examined whether P. gingivalis infection increased the invasiveness of YD10B cells. Results suggested that YD10B oral cancer cells become more aggressive when they are infected with P. gingivalis. Secondly, acetylshikonin significantly inhibited the invasion of P. gingivalis‑infected YD10B cells by suppressing IL‑8 release and IL‑8‑dependent MMP release. These data suggest that acetylshikonin may be a useful preventive and therapeutic candidate for oral cancer that is chronically infected with periodontal pathogens.

Indexed as

AnthraquinonesBacteroidaceae InfectionsCell Line, TumorCells, CulturedEpithelial-Mesenchymal TransitionGene ExpressionHumansInterleukin-8Matrix MetalloproteinasesMouth NeoplasmsPorphyromonas gingivalisacetylshikoninAnthraquinonesInterleukin-8Matrix Metalloproteinases

Identifiers

PMID29207110
PMCPMC5783479
OpenAlexW2768456066

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.